Who needs HRT alternatives — and why?
HRT remains the most effective available treatment for vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause (vaginal dryness, discomfort, urinary symptoms). For most healthy perimenopausal and menopausal women under 60 within 10 years of menopause onset, the benefits of HRT outweigh the risks — this is the current consensus from The Menopause Society and the British Menopause Society.
That said, alternatives are appropriate or preferred in several situations:
- History of hormone-sensitive cancer: Women with a personal history of estrogen receptor-positive breast cancer are typically advised against systemic HRT. Non-hormonal alternatives become the primary pharmacological path.
- Personal preference: Some women prefer to avoid exogenous hormones. Their preference is valid and should shape the clinical discussion.
- Active contraindications: Unexplained vaginal bleeding (pending workup), active or recent thromboembolic events, certain liver conditions, and other clinical factors may contraindicate HRT while being evaluated.
- Mild or single-domain symptoms: Women whose primary symptom is sleep disruption without significant vasomotor or genitourinary symptoms may find targeted non-hormonal approaches sufficient.
What non-hormonal prescription alternatives to HRT are available?
Fezolinetant (Veoza) — FDA-approved 2023
Fezolinetant is the first in a new class of non-hormonal prescription therapies for menopausal vasomotor symptoms. It works by blocking neurokinin B (NKB) receptors in the hypothalamus. NKB signaling drives the thermoregulatory dysregulation that produces hot flashes during estrogen decline. By blocking this pathway, fezolinetant reduces hot flash frequency and severity without activating estrogen receptors.
The SKYLIGHT 1 and 2 trials demonstrated significant reductions in hot flash frequency and severity versus placebo at 12 weeks, with maintained benefit at 52 weeks. Fezolinetant is the first mechanism-targeted non-hormonal FDA-approved prescription option for this indication and represents a meaningful advance over the antidepressant-class alternatives.
SSRIs and SNRIs
Several antidepressant-class medications have evidence for vasomotor symptom reduction, though the effect sizes are smaller than HRT. Paroxetine at 7.5 mg (Brisdelle) is the only SSRI/SNRI with FDA approval specifically for menopausal hot flashes. Other agents with clinical evidence include venlafaxine, desvenlafaxine, escitalopram, and citalopram.
Important considerations: standard antidepressant doses are not required for vasomotor effect (the paroxetine approval is at a sub-antidepressant dose). Tamoxifen interactions are a significant concern — paroxetine and fluoxetine inhibit CYP2D6 and can reduce tamoxifen efficacy, making them poor choices for breast cancer survivors on tamoxifen. Venlafaxine and citalopram do not carry this interaction and are often preferred in that population.
Gabapentin
Gabapentin has evidence for hot flash reduction in randomized trials, particularly at doses of 300 mg three times daily. It also has a sleep benefit profile that may make it more useful than SSRIs/SNRIs when sleep disruption is a prominent symptom. Side effects include sedation, dizziness, and cognitive effects — relevant considerations for older patients or those with specific occupational or driving needs.
Clonidine
Clonidine, a centrally acting alpha-2 agonist, has older evidence for vasomotor symptom reduction. It is used less frequently in current practice given its more prominent side effect profile (dizziness, dry mouth, sedation) and comparatively modest effect sizes. It remains an option in specific clinical contexts.
Fezolinetant is the first non-hormonal prescription to target the hypothalamic pathway behind hot flashes — without ever touching an estrogen receptor.
Comparing HRT alternatives: evidence and key considerations
| Option | Type | Primary benefit | Key consideration |
|---|---|---|---|
| Fezolinetant (Veoza) | Prescription (non-hormonal) | Hot flashes & night sweats | FDA-approved 2023; no estrogen-receptor activity |
| Paroxetine 7.5 mg | SSRI (prescription) | Hot flashes | FDA-approved for this use; avoid with tamoxifen (CYP2D6) |
| Venlafaxine / escitalopram | SNRI/SSRI (prescription) | Hot flashes, mood | Off-label; preferred over paroxetine in tamoxifen users |
| Gabapentin | Anticonvulsant (prescription) | Hot flashes, sleep | Sedation/dizziness; useful when sleep is primary complaint |
| CBT-M | Behavioral therapy | Hot flash impact, sleep, mood | Strongest behavioral evidence; does not eliminate hot flashes |
| Low-dose transdermal HRT | Hormonal (prescription) | Vasomotor + genitourinary symptoms | Requires individual risk assessment; may be suitable for HRT-hesitant women |
| Botanicals (black cohosh, soy, etc.) | OTC supplement | Inconsistent / weak | Not recommended as first-line by The Menopause Society |
Which behavioral and non-pharmacological approaches help?
Cognitive behavioral therapy (CBT)
CBT specifically adapted for menopausal symptoms (CBT-M) has the strongest evidence base among behavioral interventions. Multiple randomized controlled trials have demonstrated reductions in the perceived impact of hot flashes and night sweats, as well as improvements in sleep, mood, and quality of life. CBT-M does not eliminate hot flashes, but it can meaningfully reduce their interference with daily function.
For women with prominent anxiety, mood symptoms, or significant sleep disruption as part of their menopausal experience, CBT is particularly valuable — either alongside pharmacological treatment or as a standalone intervention.
Lifestyle interventions
Weight reduction, aerobic exercise, smoking cessation, and reduction of alcohol and caffeine have consistent evidence for reducing hot flash severity and frequency, though effects are generally modest. These interventions also carry broad cardiovascular and metabolic benefits that are independently valuable during the menopausal transition.
Sleep hygiene, cooler sleeping environments, moisture-wicking bedding, and layering strategies are low-risk quality-of-life interventions for night sweats.
Do herbal supplements work as HRT alternatives?
The supplement and botanical market for menopause is large and the evidence quality is low. A brief summary of the most frequently discussed options:
- Phytoestrogens (soy isoflavones, red clover): Some studies show modest hot flash reduction; others show no benefit. Evidence is inconsistent and the quality is limited. The Menopause Society does not recommend them as first-line alternatives. Safety in women with hormone-sensitive cancers is insufficiently characterized.
- Black cohosh: Widely used, evidence quality is poor, and several cases of hepatotoxicity have been reported. Not recommended as a standalone therapy by major menopause societies.
- Magnesium: Frequently cited online; evidence for hot flash reduction is very limited. May have sleep benefit in deficient individuals.
- Evening primrose oil: Multiple controlled trials show no benefit for hot flashes.
The pattern with botanical alternatives: they are popular, they are marketed aggressively, and the evidence for most is weak, inconsistent, or absent. A clinician discussion is more useful than a supplement trial.
Is low-dose HRT a reasonable middle path?
For women who are eligible for HRT but concerned about risks, low-dose and ultra-low-dose HRT formulations — particularly transdermal options — may offer meaningful symptom control at lower systemic hormone exposure than standard doses.
Transdermal estrogen (patches, gels, sprays) bypasses first-pass liver metabolism and produces more stable serum levels than oral formulations. Evidence suggests transdermal estrogen at low doses carries a more favorable thromboembolic risk profile than oral estrogen.
This is not a universal recommendation — your clinician evaluates your specific cardiovascular history, clotting history, breast cancer risk factors, and current symptom severity before determining whether low-dose HRT is appropriate and which formulation makes sense.
Frequently asked questions
What are the main alternatives for HRT?
The main evidence-based alternatives for HRT include fezolinetant (a neurokinin B antagonist FDA-approved for vasomotor symptoms), SSRIs and SNRIs (particularly paroxetine, escitalopram, and venlafaxine), gabapentin, clonidine, and cognitive behavioral therapy (CBT) for the psychological and sleep dimensions of menopause. None of these are as broadly effective as HRT, but each has a defined evidence base for specific symptom clusters.
Who needs HRT alternatives rather than HRT itself?
Women who are not candidates for HRT due to history of certain hormone-sensitive cancers (particularly breast cancer), personal preference for non-hormonal approaches, unexplained vaginal bleeding requiring investigation, or active thromboembolic disease may explore alternatives. A clinician review is required to determine which option fits your specific history and symptom profile.
Are herbal supplements effective alternatives to HRT?
Phytoestrogens (soy isoflavones, red clover), black cohosh, and other botanicals are widely marketed for menopausal symptoms. Evidence quality is generally low and inconsistent. The Menopause Society does not recommend these as first-line alternatives to prescription options. Some carry their own risks and drug interactions. Discuss with a clinician before starting any botanical supplement for menopause.
What is fezolinetant and how does it work as an HRT alternative?
Fezolinetant (Veoza) is an FDA-approved non-hormonal prescription medication for moderate-to-severe vasomotor symptoms (hot flashes). It works by blocking neurokinin B receptors in the hypothalamus — a pathway involved in temperature dysregulation during menopause — without affecting estrogen receptors. Clinical trials showed significant reduction in hot flash frequency and severity vs. placebo.
Can SSRIs or SNRIs help with menopausal symptoms?
Yes, for vasomotor symptoms specifically. Paroxetine (at 7.5 mg, the lowest approved dose for this indication) is FDA-approved for menopause-related hot flashes. Other SSRIs and SNRIs — including venlafaxine, escitalopram, and desvenlafaxine — have evidence supporting reduction in hot flash frequency. Effects on sleep, mood, and vaginal symptoms are more variable. Your clinician will evaluate whether an SSRI/SNRI fits your full symptom picture.
Is low-dose HRT an option for women who are concerned about risks?
For many women, the concerns driving avoidance of standard-dose HRT may be addressable with a low-dose or ultra-low-dose approach, particularly transdermal formulations that produce lower systemic hormone levels. A clinician review of your specific risk factors — including cardiovascular history, breast cancer risk, and clotting history — is essential before this decision.